Targeted Prostate Health Checks, a novel system to identify men with prostate cancer-A pilot study.
PSA
health check
multiparametric‐MRI
prostate cancer
prostate‐specific antigen
transperineal biopsy
Journal
BJUI compass
ISSN: 2688-4526
Titre abrégé: BJUI Compass
Pays: United States
ID NLM: 101764975
Informations de publication
Date de publication:
Oct 2024
Oct 2024
Historique:
received:
27
03
2024
revised:
26
06
2024
accepted:
13
07
2024
medline:
17
10
2024
pubmed:
17
10
2024
entrez:
17
10
2024
Statut:
epublish
Résumé
The objective of this study is to report the pilot phase of the Targeted Prostate Health Check programme that aims to identify men in the Surrey and Sussex region who have prostate cancer and who failed to be detected during the Covid era. Men aged 50 to 70, or 45 to 70 if Black or with a family history of prostate cancer, were identified from participating general practitioner (GP) records. Short message service (SMS) texts invited men to visit www.talkprostate.co.uk for information on prostate cancer and give consent to prostate-specific antigen (PSA) checks coordinated by a third-party virtual healthcare provider. Elevated age-related PSA levels, or levels below age-related thresholds but at 3 ng/mL or more, triggered referral to a rapid access urology clinic. GPs were informed of the results. From 1842 text messages inviting 1549 people, 544 men consented to a PSA check. From 500 phlebotomy appointments, 485 (30% of invited men) took the PSA test of whom 68 (14%) were referred with an elevated PSA. After clinical review with multiparametric magnetic resonance imaging (mp-MRI), 22 patients underwent transperineal biopsies, and prostate cancer was detected in 18 men of whom 17 (95%) had clinically significant cancer. Our Targeted Prostate Cancer Health Check system identifies men at risk without burdening primary care. Awareness on prostate cancer risk was raised in 1549 invited men, half of whom were further educated via the registration website. One third of invited men were checked in whom clinically significant prostate cancer was found in 3.5%.
Identifiants
pubmed: 39416751
doi: 10.1002/bco2.416
pii: BCO2416
pmc: PMC11479803
doi:
Types de publication
Journal Article
Langues
eng
Pagination
969-975Informations de copyright
© 2024 The Author(s). BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company.
Déclaration de conflit d'intérêts
Stephen Langley reports personal fees, non‐financial support and other from BXTAccelyon Limited, outside the submitted work. Jeremy Goad, Stephanie Bell, Lee Foster, Catherine Hodges, Marc Laniado, Michele Pietrasik, Alison Rooke, Matthew Knight, Edward Bosonnet and Simon Bott have nothing to disclose.